Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.BO)
INR 61.06
(-0.33%)
INR 61.06
(-0.33%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 400.35 Million INR | 33.29% |
| 2022 | 300.35 Million INR | 34.19% |
| 2021 | 223.82 Million INR | -37.39% |
| 2020 | 357.5 Million INR | 20.41% |
| 2019 | 296.9 Million INR | 28.37% |
| 2018 | 231.28 Million INR | 87.13% |
| 2017 | 123.59 Million INR | -8.13% |
| 2016 | 134.54 Million INR | 2.15% |
| 2015 | 131.71 Million INR | 124.71% |
| 2014 | 58.61 Million INR | -18.27% |
| 2013 | 71.71 Million INR | 19.31% |
| 2012 | 60.1 Million INR | -4.19% |
| 2011 | 62.74 Million INR | 191.52% |
| 2010 | 21.52 Million INR | 22.5% |
| 2009 | 17.56 Million INR | 29.84% |
| 2008 | 13.53 Million INR | 53.86% |
| 2007 | 8.79 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 84.43 Million INR | -44.46% |
| 2023 Q1 | 24.33 Million INR | -82.13% |
| 2023 Q3 | 50.31 Million INR | -71.03% |
| 2023 Q4 | 152.02 Million INR | 202.15% |
| 2023 FY | 400.35 Million INR | 33.29% |
| 2023 Q2 | 173.67 Million INR | 613.69% |
| 2022 Q2 | 26.19 Million INR | -78.71% |
| 2022 FY | 300.35 Million INR | 34.19% |
| 2022 Q4 | 136.15 Million INR | 811.11% |
| 2022 Q3 | 14.94 Million INR | -42.95% |
| 2022 Q1 | 123.05 Million INR | 647.83% |
| 2021 Q1 | 53.68 Million INR | -62.3% |
| 2021 FY | 223.82 Million INR | -37.39% |
| 2021 Q3 | 16.3 Million INR | -88.13% |
| 2021 Q2 | 137.37 Million INR | 155.89% |
| 2021 Q4 | 16.45 Million INR | 0.94% |
| 2020 Q4 | 142.38 Million INR | 346.07% |
| 2020 Q2 | 160.18 Million INR | 596.13% |
| 2020 Q3 | 31.92 Million INR | -80.07% |
| 2020 FY | 357.5 Million INR | 20.41% |
| 2020 Q1 | 23.01 Million INR | -38.06% |
| 2019 Q4 | 37.15 Million INR | -70.87% |
| 2019 FY | 296.9 Million INR | 28.37% |
| 2019 Q1 | 15.94 Million INR | -35.58% |
| 2019 Q2 | 116.28 Million INR | 629.49% |
| 2019 Q3 | 127.52 Million INR | 9.66% |
| 2018 Q4 | 24.74 Million INR | -82.69% |
| 2018 FY | 231.28 Million INR | 87.13% |
| 2018 Q1 | 42.24 Million INR | 18.93% |
| 2018 Q2 | 21.36 Million INR | -49.43% |
| 2018 Q3 | 142.94 Million INR | 569.2% |
| 2017 Q3 | 9.11 Million INR | 9.3% |
| 2017 Q1 | 70.63 Million INR | 12.9% |
| 2017 Q2 | 8.33 Million INR | -88.2% |
| 2017 FY | 123.59 Million INR | -8.13% |
| 2017 Q4 | 35.51 Million INR | 289.84% |
| 2016 Q3 | 39.61 Million INR | 35.47% |
| 2016 Q2 | 29.24 Million INR | 788.1% |
| 2016 Q1 | 3.29 Million INR | -93.69% |
| 2016 Q4 | 62.56 Million INR | 57.93% |
| 2016 FY | 134.54 Million INR | 2.15% |
| 2015 FY | 131.71 Million INR | 124.71% |
| 2015 Q3 | 68.94 Million INR | 1117.45% |
| 2015 Q1 | 6.91 Million INR | -81.7% |
| 2015 Q2 | 5.66 Million INR | -18.05% |
| 2015 Q4 | 52.21 Million INR | -24.27% |
| 2014 Q2 | 7.17 Million INR | 43.28% |
| 2014 Q4 | 37.75 Million INR | 334.52% |
| 2014 FY | 58.61 Million INR | -18.27% |
| 2014 Q3 | 8.68 Million INR | 21.15% |
| 2014 Q1 | 5 Million INR | -77.85% |
| 2013 Q3 | 31.23 Million INR | 242.57% |
| 2013 Q1 | 8.77 Million INR | -73.38% |
| 2013 FY | 71.71 Million INR | 19.31% |
| 2013 Q2 | 9.11 Million INR | 3.93% |
| 2013 Q4 | 22.59 Million INR | -27.65% |
| 2012 Q1 | 12.18 Million INR | -69.8% |
| 2012 Q4 | 32.94 Million INR | 316.1% |
| 2012 FY | 60.1 Million INR | -4.19% |
| 2012 Q3 | 7.91 Million INR | 12.11% |
| 2012 Q2 | 7.06 Million INR | -42.02% |
| 2011 FY | 62.74 Million INR | 191.52% |
| 2011 Q4 | 40.33 Million INR | 1003.68% |
| 2011 Q3 | 3.65 Million INR | 0.0% |
| 2010 FY | 21.52 Million INR | 22.5% |
| 2009 FY | 17.56 Million INR | 29.84% |
| 2008 FY | 13.53 Million INR | 53.86% |
| 2008 Q4 | 6.31 Million INR | 0.0% |
| 2007 FY | 8.79 Million INR | 0.0% |
| 2007 Q4 | 3.85 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Ajanta Pharma Limited | 42.08 Billion INR | 99.049% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 90.496% |
| Sigachi Industries Limited | 3.98 Billion INR | 89.965% |
| Bal Pharma Limited | 3.39 Billion INR | 88.198% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 96.874% |
| Medico Remedies Limited | 1.44 Billion INR | 72.374% |
| Lasa Supergenerics Limited | 1.04 Billion INR | 61.628% |
| Venus Remedies Limited | 5.91 Billion INR | 93.231% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | 47.005% |
| Alpa Laboratories Limited | 1.08 Billion INR | 63.182% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 97.623% |
| Shilpa Medicare Limited | 11.51 Billion INR | 96.524% |
| Aarti Drugs Limited | 25.28 Billion INR | 98.417% |
| Lupin Limited | 200.1 Billion INR | 99.8% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 99.861% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.79% |
| Windlas Biotech Limited | 6.3 Billion INR | 93.655% |
| Suven Life Sciences Limited | 116.92 Million INR | -242.39% |
| Eris Lifesciences Limited | 20.09 Billion INR | 98.007% |
| Valiant Laboratories Limited | 1.82 Billion INR | 78.009% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 98.851% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 96.767% |
| Ipca Laboratories Limited | 76.22 Billion INR | 99.475% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 94.802% |
| Achyut Healthcare Limited | 61.36 Million INR | -552.37% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.917% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 91.543% |
| RPG Life Sciences Limited | 5.82 Billion INR | 93.122% |
| Mankind Pharma Limited | 103.34 Billion INR | 99.613% |
| Laurus Labs Limited | 50.01 Billion INR | 99.2% |
| Piramal Pharma Limited | 81.71 Billion INR | 99.51% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 84.557% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 99.623% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 99.345% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 99.661% |
| Unichem Laboratories Limited | 16.57 Billion INR | 97.584% |
| Sequent Scientific Limited | 13.69 Billion INR | 97.077% |
| Novartis India Limited | 3.35 Billion INR | 88.052% |
| Wanbury Limited | 5.75 Billion INR | 93.045% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 96.192% |
| Wockhardt Limited | 27.89 Billion INR | 98.565% |
| Themis Medicare Limited | 3.81 Billion INR | 89.513% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 80.817% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 99.403% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 98.247% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.857% |
| Divi's Laboratories Limited | 78.45 Billion INR | 99.49% |
| NATCO Pharma Limited | 40.02 Billion INR | 99.0% |
| Gufic Biosciences Limited | 8.06 Billion INR | 95.037% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 98.111% |
| Ind-Swift Limited | 5.02 Billion INR | 92.032% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 96.522% |
| FDC Limited | 19.42 Billion INR | 97.939% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | 20.599% |
| Granules India Limited | 45.06 Billion INR | 99.112% |
| Medicamen Biotech Limited | 1.79 Billion INR | 77.672% |
| Alkem Laboratories Limited | 126.67 Billion INR | 99.684% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 96.91% |
| Brooks Laboratories Limited | 794.86 Million INR | 49.632% |
| Megasoft Limited | 373.95 Million INR | -7.06% |
| ZIM Laboratories Limited | 3.67 Billion INR | 89.104% |
| Strides Pharma Science Limited | 40.51 Billion INR | 99.012% |
| Neuland Laboratories Limited | 15.58 Billion INR | 97.431% |
| Morepen Laboratories Limited | 17.01 Billion INR | 97.648% |
| Hikal Limited | 17.84 Billion INR | 97.757% |
| Indoco Remedies Limited | 17.89 Billion INR | 97.763% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 97.795% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | 74.066% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | 89.138% |
| Hester Biosciences Limited | 3.04 Billion INR | 86.854% |